Peptide derived from Antibody Targeting EphA2

This peptide is derived from the EphA2 antibody and is expected to have broad applications, including use as a radiolabelled nuclear medicine therapeutic agent, a conjugate with anticancer drugs or drug delivery system (DDS) carriers, a intracellular delivery tool, and a diagnostic imaging probe.

Treatment and Biomarker for Hepatocellular Carcinoma caused by Sinusoidal Hypertension

Inhibitor of the integrin αV‒CTGF axis, which is activated in response to increased hepatic sinusoidal pressure.

Collaborative research on invasive epithelial cells in the precancerous state in interstitial pneumonia and the development of therapeutic agents

RI-labeled antibody drugs that do not accumulate in the kidney

Safe molecular design that allows RI to be rapidly excreted into the urine by providing a tubule-specific enzyme cleavage sequence between the RI chelating site and the antibody

scFv Stabilization Peptide Linker

Peptide linker enhances the interaction between VH-VL within scFv molecules, which suppresses intermolecular association.

Inducer for Systemic Anti-tumor Immunity

A novel therapeutic approach for systemic anti-tumor immunity utilizing apolipoproteins

Novel cancer immunotherapy antibodies targeting soluble CD155

Targeting soluble CD155, an immune escape mechanism of tumor cells, activates cancer immunity through DNAM-1-mediated activation signals on T cells

NF-κB inducing kinase (NIK) Novel target for cholangiocarcinoma

Molecular targeted drugs targeting the NIK associated with the differentiation factor from hepatocytes to cholangiocarcinoma

Prediction of the Efficacy of Cancer Immunotherapy by Direct Measurement of T-cell Cancer Cytotoxic Activity.

Also useful as a companion diagnostics (CDx) for immune checkpoint inhibitors (ICIs).

Liver organoid model containing human hepatocytes for pharmacokinetic assay

Original method and hepatocyte reproduced hepatobiliary function

Antibody Target against Tumor Metastases

CHRNB2, a novel target for gastric cancer, potentially other tumors

CKAP4-targeted Cancer Therapy

(Update): Anti-CKAP4 Monoclonal Antibody Obtained

Anti-CD48 Monoclonal Antibody Drug for Multiple Myeloma

Cell Surface Antigen CD48 as A Novel Molecular Target for Antibody Therapy in Multiple Myeloma

Periostin hAbs for Triple Negative Breast Cancer, Other Diseases with Unmet Needs

Investment / Co-development Opportunity for Start-up Company